Revolution Medicines Reports Extended Survival in Pancreatic Cancer Trial
Revolution Medicines announced results from a Phase 3 study of its experimental drug daraxonrasib for advanced pancreatic adenocarcinoma. Patients treated with the drug had a median survival of 13.2 months, compared to 6.7 months for those on standard chemotherapy. The company plans to seek FDA approval based on these findings.
news.google.comRevolution Medicines reported results from a Phase 3 trial of its experimental drug daraxonrasib in patients with advanced pancreatic adenocarcinoma. 7 months. The company stated it intends to submit the data to the Food and Drug Administration for approval, though no specific timeline was provided.
Details and Expert Commentary Paul Oberstein, an investigator in the trial from NYU Langone’s Perlmutter Cancer Center, discussed the results on a biotech podcast.
He described the findings as potentially significant for pancreatic cancer treatment. Oberstein noted that pancreatic cancer is challenging to treat due to its aggressive nature and limited effective therapies.
“I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.”
Pancreatic cancer has low survival rates, with current treatments offering limited benefits for advanced stages. The trial involved patients with advanced disease, comparing daraxonrasib to standard chemotherapy. Revolution Medicines indicated that approval, if granted, could occur quickly following submission.
Steps The company plans to apply for Food and Drug Administration approval using the trial data.
Further details on the submission timeline were not announced. The results were presented as part of ongoing efforts to improve outcomes in pancreatic cancer.
Transparency
Mild positive valence skew in expert commentary and word choice emphasizes potential benefits without counterpoints.
Valence skew: positive adjectives and quotes hype drug's impact on challenging cancer
While promising, the survival data is from a single trial and requires FDA review to confirm efficacy and safety before widespread use.
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Sources framed at 15; our rewrite scored 25 — in line with the sources.
Story details
Related Stories
nypost.comBundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italy
Four nurses and one laboratory worker have recovered from Ebola caused by the Bundibugyo strain in the Democratic Republic of Congo. Suspected cases linked to travel from affected countries are under investigation in Brazil and Italy.
New ScientistPhase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer
A 500-person study found the once-daily pill halted or reversed tumor progression in nearly one-third of patients versus 10 percent on chemotherapy. Median survival rose from less than seven months to roughly 13 months.
Wildfire Insured Losses Hit $54 Billion in 2025, Highest on Record
A new analysis published Sunday found that insured losses from wildfires worldwide hit at least $54 billion in 2025, the highest level on record. The Los Angeles fires and blazes in South Korea and Spain drove the total.